Cisen Pharmaceutical Co Ltd (603367) - Total Liabilities
Based on the latest financial reports, Cisen Pharmaceutical Co Ltd (603367) has total liabilities worth CN¥1.29 Billion CNY (≈ $189.23 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cisen Pharmaceutical Co Ltd - Total Liabilities Trend (2011–2025)
This chart illustrates how Cisen Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 603367 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Cisen Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Cisen Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BW Offshore Ltd
OL:BWO
|
Norway | Nkr3.04 Billion |
|
uPI Semiconductor Corp
TW:6719
|
Taiwan | NT$2.87 Billion |
|
JOST Werke AG
XETRA:JST
|
Germany | €1.27 Billion |
|
SG Fleet Group Ltd
AU:SGF
|
Australia | AU$2.91 Billion |
|
Shandong Xinhua Pharmaceutical Co Ltd
SHE:000756
|
China | CN¥3.87 Billion |
|
Fujian Longma Envi Sanitation
SHG:603686
|
China | CN¥3.36 Billion |
|
Center Laboratories
TWO:4123
|
Taiwan | NT$6.17 Billion |
|
Gryphon Capital Income Trust
AU:GCI
|
Australia | AU$7.51 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Cisen Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cisen Pharmaceutical Co Ltd (603367) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cisen Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cisen Pharmaceutical Co Ltd (2011–2025)
The table below shows the annual total liabilities of Cisen Pharmaceutical Co Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.37 Billion ≈ $200.00 Million |
-12.77% |
| 2024-12-31 | CN¥1.57 Billion ≈ $229.28 Million |
-0.29% |
| 2023-12-31 | CN¥1.57 Billion ≈ $229.94 Million |
+7.68% |
| 2022-12-31 | CN¥1.46 Billion ≈ $213.53 Million |
+11.55% |
| 2021-12-31 | CN¥1.31 Billion ≈ $191.42 Million |
-4.08% |
| 2020-12-31 | CN¥1.36 Billion ≈ $199.56 Million |
+42.06% |
| 2019-12-31 | CN¥959.97 Million ≈ $140.47 Million |
-12.20% |
| 2018-12-31 | CN¥1.09 Billion ≈ $160.00 Million |
+7.45% |
| 2017-12-31 | CN¥1.02 Billion ≈ $148.91 Million |
+3.60% |
| 2016-12-31 | CN¥982.26 Million ≈ $143.74 Million |
+5.02% |
| 2015-12-31 | CN¥935.33 Million ≈ $136.87 Million |
+18.03% |
| 2014-12-31 | CN¥792.44 Million ≈ $115.96 Million |
+24.50% |
| 2013-12-31 | CN¥636.48 Million ≈ $93.14 Million |
+35.40% |
| 2012-12-31 | CN¥470.06 Million ≈ $68.79 Million |
+104.36% |
| 2011-12-31 | CN¥230.02 Million ≈ $33.66 Million |
-- |
About Cisen Pharmaceutical Co Ltd
Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products. The company's chemical preparations include basic infusion, therapeutic infusion, liver disease medication, nervous system drugs, anti-tumor and adjuvant drugs, nutritional infusion, contrast agents, cardiovascular and cerebrovascular drugs, anti-infective drugs, anesthetic and a… Read more